HOME >> BIOLOGY >> NEWS
New strategy rapidly identifies cancer targets

In a step toward personalized medicine, Howard Hughes Medical Institute investigator Brian J. Druker and colleagues have developed a new technique to identify previously unknown genetic mutations that can trigger cancerous growth. By analyzing the proteins instead of the genes inside acute myeloid leukemia (AML) cells, the researchers have dramatically reduced the time it takes to zero in on molecular abnormalities that might be vulnerable to specific drug treatments.

"This approach gives us a way to figure out what's driving the growth of a cancer in an individual patient and ultimately match that patient with the right drug," said Druker, who is based at the Oregon Health & Science University in Portland. Druker's team collaborated on the research, which was published in the July 17, 2006, issue of the journal Cancer Cell, with scientists in the lab of D. Gary Gilliland, an HHMI investigator at Brigham and Women's Hospital, as well as researchers at the Portland VA Medical Center, Cell Signaling Technology, the University of Chicago, and Yale University.

Traditionally, cancer-gene hunters have scanned the genome looking for mutations that trigger out-of-control cell growth. Druker tried this approach, but found it wanting. "We were doing some high-throughput DNA sequencing, and we weren't really finding much," he said.

Instead, the team added tools from the burgeoning field of proteomics, the study of proteins. "We decided this more functional assay would get us to the disease-causing genes more rapidly," said Druker, who has been studying a group of cell-signaling proteins called tyrosine kinases for 20 years.

Tyrosine kinases play a key role in many cancers. In healthy cells, they help form a chain of signals that prompt normal cell growth and division. Sometimes, though, a tyrosine kinase gets stuck in an "on" position, driving out-of-control cell division and, ultimately, cancer. This potentially devastating kinase act
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
16-Jul-2006


Page: 1 2 3

Related biology news :

1. New strategy for treating allergic disorders
2. Does EPA have an adequate strategy to oversee nanotechnologies?
3. High blood pressure medication strategy proves effective in Hispanic women
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Scientists identify new strategy for preventing acute and chronic brain disease
6. International risk research strategy and funding needed for nanotech safety
7. Study shows metabolic strategy of stressed cell
8. Trojan horse strategy defeats drug-resistant bacteria
9. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
10. Drug strategy makes cancer genes get lost in translation
11. Researchers develop new strategy for the treatment of CML

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced today its plans to ... and Pain Management-Driven ASC Conference in Chicago on Thursday, June 13th at 6:30 pm. ... Chicago, IL in the 3rd floor Ticino Hospitality room in space #74T. , The ...
(Date:6/6/2019)... ... June 05, 2019 , ... MedTech ... the global health and medical technology market, announced that it has selected Medacta ... Robotics Solution” award in the 2019 MedTech Breakthrough Awards program. , ...
(Date:6/4/2019)... ... June 04, 2019 , ... Molecular Devices, a global leader ... the new President of Molecular Devices, replacing Greg Milosevich who has been appointed ... , Since joining Molecular Devices in a scientific engineering role, Ms. Murphy has ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary ... of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of ... cells with engineered T cell receptors known as “CARs”. The CAR enables the final ...
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
(Date:5/14/2019)... Calif. (PRWEB) , ... May 14, 2019 , ... ... office expansion, effectively doubling its space from 2,500 to 5,000 square feet. , ... Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home ...
(Date:5/2/2019)... BELTSVILLE, Md. (PRWEB) , ... ... ... certification to the International Organization for Standardization ISO 9001:2015 standard, REPROCELL USA ... consistently meet customer requirements. In addition, REPROCELL USA Inc. aims to enhance ...
Breaking Biology Technology:
Cached News: